Company Overview and News

 
Queensland Bauxite secures medical cannabis import and export licences

2018-07-18 proactiveinvestors.com.au
Queensland Bauxite Ltd (ASX:QBL) through Medcan Australia has been issued with both import and export licences under the Office of Drug Control.
QBL

 
Boxing clever Gina outmuscles Twiggy in fight for Atlas

2018-06-18 theage.com.au
There will be no love lost in the battle for control of Atlas Iron, but the bidding documents from Gina Rinehart’s crew suggests the $390 million cash bid is not just an opportunity to rankle her Perth neighbour Andrew ‘Twiggy’ Forrest.
AGO QBL ATLGF AGODY

 
Boxing clever Gina outmuscles Twiggy in fight for Atlas

2018-06-18 smh.com.au
There will be no love lost in the battle for control of Atlas Iron, but the bidding documents from Gina Rinehart’s crew suggests the $390 million cash bid is not just an opportunity to rankle her Perth neighbour Andrew ‘Twiggy’ Forrest.
AGO QBL ATLGF AGODY

 
Catherine Brenner will finally face the music - at Coke AGM not AMP

2018-05-13 theage.com.au
It should have been a momentous occasion marking the progress of women into the top positions at one of Australia's bluest of blue chip corporations.
QBL

 
Catherine Brenner will finally face the music - at Coke AGM not AMP

2018-05-13 smh.com.au
It should have been a momentous occasion marking the progress of women into the top positions at one of Australia's bluest of blue chip corporations.
QBL

 
The Agency in the market for an underwriter

2018-04-24 theage.com.au
What is it with real estate agencies that go public? Having left John McGrath's busines post its listing and sold their shares out of escrow, The Agency mob, formerly Ausnet based in Perth, has lost their underwriter for the proposed 550 million share issue - at 2¢. The company conveniently announced it had lost the underwriter late last Friday afternoon after trading closed.
QBL

 
The Agency in the market for an underwriter

2018-04-24 smh.com.au
What is it with real estate agencies that go public? Having left John McGrath's busines post its listing and sold their shares out of escrow, The Agency mob, formerly Ausnet based in Perth, has lost their underwriter for the proposed 550 million share issue - at 2¢. The company conveniently announced it had lost the underwriter late last Friday afternoon after trading closed.
QBL

 
Queensland Bauxite selling hemp products in Coles, shares rise

2018-04-19 proactiveinvestors.com.au
Queensland Bauxite Ltd (ASX:QBL) through its subsidiary Medical Cannabis Limited (MCL) is now supplying Coles stores with hemp products around Australia.
QBL

 
Former Babcock & Brown duo catch the SurfStitch wave

2018-03-19 theage.com.au
Fresh from rescuing women’s fashion group Noni B, the former Babcock & Brown duo Trevor Loewensohn and Phil Green, have now set their sights on salvaging the waterlogged SurfStitch business.
NBL QBL

 
Former Babcock & Brown duo catch the SurfStitch wave

2018-03-19 smh.com.au
Fresh from rescuing women’s fashion group Noni B, the former Babcock & Brown duo Trevor Loewensohn and Phil Green, have now set their sights on salvaging the waterlogged SurfStitch business.
NBL QBL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...